Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2016

View Archived Issues

Cannabinoids block the inflammatory response caused by beta-amyloid proteotoxicity

Hitgen discloses HDAC inhibitors

Swansea University and The University of Bath jointly patent antibacterial compounds

Merck & Co. patents BTK inhibitors

Galderma Pharma reports RORgamma inverse agonists

Bayer Healthcare announces MPGES-1 inhibitors

Charles University in Prague discloses compounds to treat tuberculosis

TenNor Therapeutics describes development of TNP-2092 for H. pylori infection

Shionogi announces agreements on collaborative research

First-patient enrolled in phase I/II study of OTS-167 in AML

Phase III GOYA trial of Gazyva in DLBCL misses primary endpoint

F-star extends collaboration and funding arrangement with CD Laboratory

EMA accepts for review MAA for adalimumab biosimilar SB-5

Updates on novel strategies with CD19-specific CAR-modified T cells

Anti-endoglin MAb for Ewing sarcoma

Cladribine tablet MAA accepted for review by EMA

OncBioMune Pharmaceuticals submits clinical protocol for ProscaVax in Mexico

Phase III AURA3 trial of Tagrisso in second-line NSCLC meets primary endpoint

VLP Therapeutics wins award to develop malaria vaccine

Cervarix approved in China

Clinuvel updates U.S. regulatory progress for Scenesse

Tivorsan's TVN-102 receives U.S. orphan drug designation for DMD

NUAK1-selective small-molecule inhibitors may be useful for treatment of colorectal cancer

Diamyd Medical and UCLA to advance preclinical research in type 1 diabetes

PATZ1 expression correlated with survival in diffuse large B-cell lymphomas

FDA grants orphan drug designation to florilglutamic acid (18F)

HYD Pharma gains Slovakian ethics approval for phase II trial to study DDW in CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...